Erin Mobley, Ph.D., is the first author of a new study finding that the heart-protective drug dexrazoxane significantly reduced chemotherapy-related heart damage for years after treatment.
Researchers are helping advance practical strategies to prevent cancer, improve early detection and strengthen survivorship care.
The project aims to uncover the reasons for the difference in treatment delivered for Hodgkin lymphoma.
In an interview with Healio, Erin Mobley, Ph.D., discussed her study on the cardioprotective effects of dexrazoxane in pediatric cancer survivors.
The award recognizes her research on cardiac function after doxorubicin and dexrazoxane.
Erin Mobley's childhood journey shaped her career pathway as a cancer researcher.
